Role of Aspirin in High Pulsatility Index of Uterine Artery: A Consort Study

  • Nidhi Sharma
  • Sunayana Srinivasan
  • K. Jayashree Srinivasan
  • Kulasekaran Nadhamuni
Original Article



Preeclampsia is a heterogeneous disorder prevalent in 3–10% of pregnant women globally. The etiology is multifactorial. There is a initial stage of endothelial dysfunction and placental ischemia (Stage 1); this leads to maternal syndrome of hypertension, edema, and proteinuria (Stage 2). Drugs acting on immunomodulatory, anti-inflammatory, antioxidant and proresolving pathways can minimize the complications of preeclampsia. The therapeutic effect of aspirin is based on acetyl group and salicylate group. Both components have independent therapeutic effects on anti-inflammatory pathway and proresolving pathway.

Aims and Objectives

This study was designed to assess the effectiveness and safety of aspirin in prevention and treatment of symptoms and complications of preeclampsia in women at high risk of preeclampsia.


This is a prospective experimental study to evaluate the effectiveness of aspirin versus placebo in the prevention of maternal syndrome of preeclampsia in women with high risk of preeclampsia (G1 = 97, G2 = 92). Patients with age ≥ 34, chronic hypertension, multiple pregnancies, gestational diabetes, and high pulsatility index of uterine artery were enrolled between 12 and 20 weeks of gestation and prescribed 75 mg aspirin daily till 34 weeks of gestation. Control group was not prescribed aspirin.

Observations and Results

There was a reduction in relative risk of preeclampsia in aspirin group as compared with control group. There was no significant increase in the number of cases of abruption placenta, preterm delivery, neonatal intraventricular hemorrhage, patent ductus arteriosus, and postpartum hemorrhage following aspirin therapy.


In patients with high mean pulsatility index of uterine arteries, low dose aspirin can be a useful intervention. Uterine artery Doppler is a simple and noninvasive test which can be used safely for the prediction of preeclampsia. Aspirin is safe, economical, and easily available commercially.


Acetylsalicylic acid Preeclampsia Uterine artery Doppler Ultrasound 



We thank our staff and Obstetrics and Gynecology outpatient staff for helping in the care given to the patients.

Compliance with Ethical Standards

Conflict of interest

The authors declare that there is no conflict of interest. We do not have any commercial association that might pose a conflict of interest in connection with the manuscript. We certify that neither this manuscript nor one with substantially similar content under our authorship has been published or is being considered for publication elsewhere.

Ethical Clearance

Ethical Committee approval was obtained from the Institutional Research Board.

Informed Consent

The research participants were informed about the study in local language and informed written consent was taken after explaining the nature of ultrasound Doppler scan in pregnancy. We have obtained the patient’s consent for participation in research. Ethical committee clearance and research board clearance was obtained for this study according to the Principle of Helsinki.


  1. 1.
    Adu Bonsaffoh K, Samuel OA, Binlinha G. Maternal death attributable to hypertensive disorders in tertiary hospital in Ghana. Int J Gynaecol Obstet. 2013;123:110–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of preeclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynecol. 2011;25:391–403.CrossRefGoogle Scholar
  3. 3.
    Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376(9741):631–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Roberts JM, Hubel CA. The two-stage model of preeclampsia: variations on the theme. Placenta. 2009;30(Supple A):S32–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Ahmed A, Ramma W. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? Br J Pharmacol. 2015;172(6):1574–86.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bujold E, Roberge S, Lacasse Y, Bureau M, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta analysis. Obstet Gynaecol. 2010;116(2):402–14.CrossRefGoogle Scholar
  7. 7.
    Schrör K. Acetylsalicylic acid. Weinheim: Wiley; 2010.Google Scholar
  8. 8.
    Alverez AM, Mulla MJ, Chamely LW, Cadavid AP, et al. Aspirin triggered lipoxins prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions. Arthritis Rheumatolol. 2015;67(2):488–97.CrossRefGoogle Scholar
  9. 9.
    Madariaga-Venegas F, Fernández-Soto R, Duarte LF, Suarez N, et al. Characterization of a novel antibiofilm effect of nitric oxide-releasing aspirin (NCX-4040) on Candida albicans isolates from denture stomatitis patients. PLoS ONE. 2017;12(5):e0176755. doi: 10.1371/journal.pone.0176755.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lausman A, Kingdom J, Bradley T. Subclinical atherosclerosis in association with elevated placental vascular resistance in early pregnancy. Atherosclerosis. 2009;. doi: 10.1016/j.atherosclerosis.2009.02.007.PubMedGoogle Scholar
  11. 11.
    Llurba E, Carreras E, Gratacós E, et al. Maternal history and uterine artery Doppler in the assessment of risk for development of early- and late-onset preeclampsia and intrauterine growth restriction. Obstet Gynecol Int. 2009;. doi: 10.1155/2009/275613.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Everett TR, Mahendru AA, McEniery CM, Wilkinson IB, et al. Raised uterine artery impedance is associated with increased maternal arterial stiffness in the late second trimester. Placenta. 2012;33(7):572–7. doi: 10.1016/j.placenta.2012.04.001.CrossRefPubMedGoogle Scholar
  13. 13.
    Khan F, Mires G, Macleod M, et al. Relationship between maternal arterial wave reflection, micro vascular function and fetal growth in normal pregnancy. Microcirculation. 2010;17:608e.CrossRefGoogle Scholar
  14. 14.
    Enkhmaa D, Wall D, Mehta PK, Stuart JJ, et al. Preeclampsia and vascular function: a window to future cardiovascular disease risk. J Women’s Health. 2016;. doi: 10.1089/jwh.2015.5414.Google Scholar
  15. 15.
    Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261. doi: 10.3389/fimmu.2017.00261.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Papageorghiou AT, Yu CK, Bindra R, Pandis G, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol. 2001;18(5):441–9. doi: 10.1046/j.0960-7692.2001.00572.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Cnossen J, Morris R, Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178:701–11.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol. 2008;79(8 Suppl):1520–6. doi: 10.1902/jop.2008.080231.CrossRefPubMedGoogle Scholar
  19. 19.
    Gil Villa AM, Norling LV, Serhan CN, Cordero D, et al. Aspirin triggered Lipoxin A 4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot Essential Fatty Acids. 2012;87(4–5):127–34.CrossRefGoogle Scholar
  20. 20.
    Dalli J, Winkler JW, Colas RA, Arnardottir H, et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol. 2013;20(2):188–201. doi: 10.1016/j.chembiol.2012.11.010.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Romano M. Lipoxin and aspirin-triggered lipoxins. Sci World J. 2010;2(10):1048–64. doi: 10.1100/tsw.2010.113.CrossRefGoogle Scholar
  22. 22.
    Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol. 2009;158(4):947–59. doi: 10.1111/j.1476-5381.2009.00386.x.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Atarod Z, Kiani LA, Hashemi SA, et al. Effects of low dose aspirin in the prevention of preeclampsia in pregnant women with abnormal uterine artery Doppler at 11-14 weeks of gestation. Med J Obstet Gynecol. 2015;3(5):1068.Google Scholar
  24. 24.
    Cantu JA, Jauk VR, Owen J, Biggio JR, et al. Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy? J Matern Fetal Neonatal Med. 2015;28(10):1128–32. doi: 10.3109/14767058.2014.947258.CrossRefPubMedGoogle Scholar
  25. 25.
    Meher S, Alfirevic Z. Aspirin for pre-eclampsia: beware of subgroup meta-analysis. Ultrasound Obstet Gynecol. 2013;41:479–85. doi: 10.1002/uog.12470.CrossRefPubMedGoogle Scholar
  26. 26.
    Scifres CM, Iams JD, Klebanoff M, et al. Metaanalysis vs large clinical trials: which should guide our management? Am J Obstet Gynecol. 2009;200(484):e1–5.CrossRefGoogle Scholar
  27. 27.
    Thornton J. Commentary on aspirin for prevention of preeclampsia in high-risk women. BJOG. 2013;120:74–5.CrossRefGoogle Scholar
  28. 28.
    Villa P, Kajantie E, Räikkönen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013;120:64–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Bujold E, Roberge S, Lacasse Y, Bureau M, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14.CrossRefPubMedGoogle Scholar
  30. 30.
    Bujold E, Morency AM, Roberge S, Lacasse Y, et al. Gigue`re Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2009;31:818–26.CrossRefPubMedGoogle Scholar
  31. 31.
    Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31:141–6.CrossRefPubMedGoogle Scholar
  32. 32.
    America College of Obstetrician and Gynecologist. Task force on hypertension in pregnancy. Report of the American college of Obstetrician and gynecologist’s task force on Hypertension in pregnancy. Obstet Gynaecol. 2013;122(5):1122–31.CrossRefGoogle Scholar
  33. 33.
    Mone F, Mulachy C, Mcparland P, et al. Should we recommend universal aspirin for all pregnant women? Am J Obstet Gynaecol. 2017;216(2):141e1–5.CrossRefGoogle Scholar
  34. 34.
    Schisterman EF, Silver RM, Lesher LL, et al. Preconceptional low dose aspirin and pregnancy outcomes: results from EAGeR randomized trial. Lancet. 2014;384(9937):29–36.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2017

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynaecology, Saveetha Medical CollegeSaveetha UniversityChennaiIndia
  2. 2.Good Samaritan Medical CentreWest IslipUSA
  3. 3.VelacheryIndia

Personalised recommendations